Overview

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Status:
Terminated

Trial end date:
2020-10-27

Target enrollment:

Participant gender:

Summary

The purpose of this phase 1 study is to evaluate the safety and anti-tumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in participants with Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Phase:

Phase 1

Details

Lead Sponsor:

ADC Therapeutics S.A.

Treatments:

Antibodies, Monoclonal
Durvalumab
Loncastuximab tesirine